Symposium

[GS02] Development of DDS technology for nucleic acid drugs and gene therapeutics --From control of pharmacokinetics and intracellular trafficking to therapeutic application--

Sat. Mar 27, 2021 3:45 PM - 5:45 PM [Room F] Oral Presentation F (Online)

Organizer: Kimura Seigo (Fac. Pharmaceut. Sci., Hokkaido Univ.), Kato Naoya (Grad. Sch. Biomed. Sci., Nagasaki Univ.)

In this era, the concept of pharmaceuticals has expanded from small molecule drugs to macromolecule drugs, leading to novel therapeutic strategies such as gene therapy and regenerative medicine. Especially, nucleic acid-based therapeutics have begun to be approved in Japan such as Spinraza®, Onpattro®, and Collategen® in recent years, and further development as a new therapeutic method for incurable diseases is expected. The key factor determining the therapeutic effect of nucleic acid-based therapeutics is how to deliver them to the site of action of target tissues/cells. Due to their low membrane permeability and difficulty in controlling their biodistribution, nucleic acid-based therapeutics is the field where DDS technology is most needed. In recent decades, various nucleic acid and gene delivery technologies such as lipid nanoparticles, micelles, and conjugates have been developed and studied. In this symposium, we will learn how these technologies can overcome the barriers that exist in the process of nucleic acid delivery in vivo, and discuss methodologies for controlling the biodistribution and intracellular trafficking of them.

+Add all to schedule

オーガナイザー挨拶（趣旨説明）：加藤直也（長崎大院医歯薬） (3:45 PM - 3:50 PM)

3:50 PM - 4:08 PM

[GS02-1] Development of the efficient and selective delivery carrier of plasmid DNA to immune cells in the spleen and its potential applicability to DNA vaccines

○Seigo Kimura¹, Ikramy Khalil², Hideyoshi Harashima¹ (1. Fac. Pharmaceut. Sci., Hokkaido Univ., 2. Dept. Pharmaceut., Assuit Univ.)

4:08 PM - 4:26 PM

[GS02-2] Nanoparticle design for lymphatic transport and application to nucleic acid delivery

○Masaki Gomi¹, Yu Sakurai¹, Naoya Miura¹, Hiroki Tanaka¹, Hidetaka Akita¹ (1. Grad. Sch. Pharm. Sci., Chiba Univ.)

4:26 PM - 4:44 PM

[GS02-3] Development of artificial nucleic acids toward oligonucleotide therapeutics for the hypoxia-selectivity and catalytic target RNA cleavage

○Akira Yano^1,2, Masahito Inagaki^1,2, Tsuyoshi Yamamoto³, Masaki Nishijima^1,2, Yasuyuki Araki^1,2, Satoru Ishibashi⁴, Asako Yamayoshi³, Takanori Yokota⁴, Takehiko Wada^1,2 (1. Grad. Sch. Sci. Dept. Chem., Tohoku Univ., 2. IMRAM., Tohoku Univ., 3. Grad. Sch. Biomed. Sci., Nagasaki Univ., 4. Dept. Neuro. NeuroSci., Tokyo Med Dent Univ.)

4:44 PM - 5:02 PM

[GS02-4] Development of ultrasmall oligonucleotide delivery system for treating intractable cancers by fine-tuning of polymer material and oligonucleotide structures

○Hiroyuki Chaya¹, Sumiyo Watanabe², Kotaro Hayashi³, Kazuko Toh³, Hyun Jin Kim², Mitsuru Naito², Beob Soo Kim¹, Kazunori Kataoka^3,4, Kanjiro Miyata¹ (1. Grad. Sch. Eng., UTokyo, 2. Grad. Sch. Med., UTokyo, 3. iCONM, 4. IFI, UTokyo)

5:02 PM - 5:20 PM

[GS02-5] Design of efficient delivery carrier for CRISPR-Cas9 system

○Toru Taharabaru¹, Takuya Kihara¹, Risako Onodera¹, Keiichi Motoyama¹, Taishi Higashi^1,2 (1. Kumamoto Univ. Grad. Sch. Pharm.Sci., 2. Priority Organization for Innovation and Excellence, Kumamoto Univ.)

5:20 PM - 5:38 PM

[GS02-6] Development strategy for brain-targeted nanoparticles utilizing multi-color deep imaging

○Naoya Kato¹, Hidefumi Mukai¹, Shigeru Kawakami¹ (1. Grad. Sch. Biomed. Sci., Nagasaki Univ.)

総括：木村誠悟（北大院薬） (5:38 PM - 5:45 PM)

Session information